Key points are not available for this paper at this time.
In the United States, this real-world study compared the effectiveness of dupilumab, benralizumab, and mepolizumab in reducing exacerbations and systemic corticosteroid (SCS) prescriptions among patients with asthma.
Bleecker et al. (Sat,) studied this question.